This is a preview and has not been published.

Revision of some Biomarkers with Cytokines in Breast Cancer




Breast cancer, Catalase, Cytokines, Malondialdehyde, 8-Nitroguanine


Breast cancer is the most repeatedly detected cancer category and the second reason cause of cancer-linked deaths among women worldwide. Tumor bio-indictor is a term utilized to describe possible indicators for carcinoma diagnosis, development and progression. The goal of this study is to evaluate part of some cytokines and biomarkers for both serum and saliva samples in breast cancer then estimate their potential value in the early diagnosis of breast cancer by doing more researches in saliva, and utilizing saliva instead of blood (serum and plasma) in sample collection from patients. Serum and salivary samples were taken from 72 patients with breast cancer and 45 healthy controls, in order to investigate the following cytokines such as: interleukin 12 (IL-12), interleukin 6 (IL-6), interleukin 4 (IL-4), 8-hydroxydeoxyguanosine (8-OHdG), tumor necrosis factor (TNF) and interferon-γ (IFN-γ) levels with other bio-pointers such as:
 malondialdehyde (MDA), catalase, and 8-nitroguanine (8-NG). The results displayed  that the levels of blood and saliva samples of IL-12 (P<0.0001), IL-6 (P<0.0001), IL-4 (P<0.001), 8-OHdG (P<0.0001), 8-NG (P<0.001, and P<0.004), TNF (P<0.002, and P<0.001)  and IFN-γ (P<0.0001) were significantly higher in breast cancer, whereas there were significant lowering (P<0.0001)  in catalase activates in breast cancer in both samples as compared with healthy subjects. The exchanging of blood to salivary components evaluation in this investigation may be utilized as a diagnostic tool, and designates the potential part for MDA, Catalase, and cytokines as important biochemical in breast cancer. Accordingly, the salivary diagnosis embraces a non-invasive process and tumor progression in breast malignancy patients. Beside saliva may well signify as an active new gate as blood evaluation but easier and cheaper.


Download data is not yet available.


Hussain AM, Mohammed AL-Khafaji AH, Ali AH, Mohammed HL. Study of certain biomarkers in Iraqi female patients with breast cancer. Baghdad Sci J. 2021; 18(4): 1140.

Li CJ, Chen HM, Lai JC. Diagnostic, prognostic, and predictive biomarkers in breast cancer. J Oncol. 2020; 1- 2, ID 1835691.

DeSantis CE, Ma J , Gaudet MM, Newman LA, Miller KD , Sauer AG, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6): 438-51. doi: 10.3322/caac.21583.

Aliyev AT, Panieri E , Stepani´c V , Gurer-Orhan H, Saso L. Involvement of NRF2 in breast cancer and possible therapeutical role of polyphenols and melatonin. Molecules. 2021; 26: 1853.

Al-Hassnawi ATS, Al-Morshidy KAH, Al-Harbi NY. Milk tumor necrosis factor alpha and interleukin-1beta among toxoplasma gondii-free and infected women. Baghdad Sci J. 2021; 19(1): 0001.

Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J. Interferon Cytokine Res. 2015; 35(1): 1-16.

Fasoulakis Z, Kolios G, Papamanolis V, Kontomanolis EN. Interleukins Associated with Breast Cancer. Cureus. 2018; 10(11): e3549.

Jiang XP, Yang DC, Elliott RL, Head JF. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. Anticancer Res. 2011;31:2899-2906.

Gulcin I. Antioxidants and antioxidant methods-An updated overview. Arch Toxicol. 2020; 94(3): 651-715

Gulcin I. Antioxidant activity of eugenol-a structure and activity relationship study. J Med Food. 2011; 14(9): 975-985.

Gulcin I. Antioxidant activity of food constituents: An overview. Arch Toxicol. 2012; 86(3): 345-391

Qing X, Shi1 D, Lv X , Wang B, Chen S, Shao Z. Prognostic significance of 8-hydroxy-2′- deoxyguanosine in solid tumors: a metaanalysis. BMC Cancer. 2019; 19: 997.

Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2 -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C. 2009; 27: 120-139.

Verigos KE, Sagredou S , Orfanakos K, Dalezis P, Trafalis DT. 8-Hydroxy-2’-deoxyguanosine and 8-nitroguanine production and detection in blood serum of breast cancer patients in response to postoperative complementary external ionizing irradiation of normal tissues. Dose-Resonse. 2020.

Mirlekar B , Pylayeva-Gupta Y. Review IL-12 family cytokines in cancer and immunotherapy. Cancers. 2021; 13: 167.

Kwon Y. Possible beneficial effects of N-acetylcysteine for treatment of triple-negative breast cancer. Antioxidants. 2021; 10: 169.

Papila KB, Volkan S , Sinem D; Cigdem KP, Orkun KF; Cigdem P, et al. The evaluation of oxidative stress parameters in breast and colon cancer. Medicine. 2021; 100(11); e25104

Idris A, Ghazali NB, Koh D. Interleukin 1β—a potential salivary biomarker for cancer progression? Biomark Cancer. 2015; 7: 25-29.

Lan T, Chen L, Wei X. 1Inflammatory cytokines in cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells 2021; 10: 100.

Amin MN, Siddiqui SA, Ibrahim M, Hakim ML, Ahammed MS, Kabir A, et al. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med. 2020; 8: 2050312120965752.

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014; 2014: 149185.

Sánchez-Zauco N , Torres J , Gómez A, Camorlinga-Ponce M , Muñoz-Pérez L, Herrera-Goepfert R, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. BMC Cancer. 2017; 17(1): 384.

Al-Ghurabi BH. IL-2 and IL-4 serum levels in breast cancer. J Fac Med Baghdad. 2009; 51(3): 300-303.

Shi J , Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021; 22: 2998.

Hussein MZ, Al Fikky A, Abdel Bar I. Serum IL-6 and IL-12 levels in breast cancer patients Egypt J Immunol. 2004; 11(2): 165-70.

Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat. 2011; 133(3): 881-888.

Mercogliano MF, Bruni S, Mauro F, Elizalde PV, Schillaci R .Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy. Cancers. 2021; 13: 564

Greish, K, Taurin, S, Morsy MA. The effect of adjuvant therapy with TNF-α on animal model of triple-negative breast cancer. Ther Deliv. 2018; 9: 333-342.

Borj MR, Andalib AR, Mohammadi A, Hoseiniharouni SM, Pourghadamyari H, Azizi H, et al Evaluation of IL-4, IL-17, and IFN-γ levels in patients with breast csancer. Int J Basic Sci Med. 2017; 2(1): 20-24

AL-Musawi AK, Al-Rubae'i SHN, Mahdi MF. Role of caspase-3, IL-1β and oxidative stress in Iraqi women with breast cancer. The International Conference of Chemistry 2020. J. Phys. Conf. Ser. 2021; 1853: 012050 doi:10.1088/1742-6596/1853/1/012050

Suzuki H, Nishizawa T. Oxidative stress and stomach cancer. Cancer. 2014: 33-40. DOI:10.1016/B978-0-12-405205-5.00004-0

Salman RA, Al-Bairuty GAA, Abdul-Rasheed OF. Decreased catalase activity and glutathione concentration levels in women patients with breast cancer. Ann Trop Med Public Health. 2020; 23(13): 231-371.

Glorieuxa C, Calderon PB. Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. Biol Chem. 2017; 398(10): 1095–1108

Hwang TS, Choi HK, Han HS. Differential expression of manganese superoxide dismutase, copper/zinc superoxide dismutase, and catalase in gastric adenocarcinoma and normal gastric mucosa. Eur J Surg Oncol. 2007; 33(4): 474-9.

Sawczuk B, Maciejczyk M, Sawczuk-Siemieniuk M, Posmyk R, Zalewska A, Car H.Salivary gland function, antioxidant defence and oxidative damage in the saliva of patients with breast Cancer: does the BRCA1 Mutation disturb the salivary redox profile? Cancers. 2019; 11: 1501. doi:10.3390/cancers11101501

Bel’skaya LV, Kosenok VK. The level of cytokines in the saliva of patients with breast cancer. ВОПРОСЫ ОНКОЛОГИИ. 2019; 65(6): 825-831

Porto-Mascarenhas EC, Assad DX, Chardin H, Gozal D, GDL Canto, Acevedo AC, et al. Salivary biomarkers in the diagnosis of breast cancer: a review. Crit Rev Oncol Hematol.2017; 110: 62-73.

Zalewska A, Waszkiewicz N , López-Pintor RM. The Use of saliva in the dagnosis of oral and systemic diseases. Dis Markers.2019: 1-2. ID 9149503

Dawood RM, Hasan HR, Assessment of salivary and serum proteins in patients with oral tumors. Baghdad Sci J. 2013; 10(3): 934-44